Improving human kidney function in renovascular disease with mesenchymal stem cell therapy
Authors:
- 1 April 2020
- journal article
- editorial
- Published by Elsevier in Kidney International
- Vol. 97 (4) , 655-656
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council
This publication has 7 references indexed in Scilit:
- In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressureKidney International, 2020
- Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic OpportunitiesCell Stem Cell, 2018
- IL-17A improves the efficacy of mesenchymal stem cells in ischemic-reperfusion renal injury by increasing Treg percentages by the COX-2/PGE2 pathwayKidney International, 2018
- Interleukin-17A-Induced Human Mesenchymal Stem Cells Are Superior Modulators of Immunological FunctionStem Cells, 2015
- Interferon-Gamma Modification of Mesenchymal Stem Cells: Implications of Autologous and Allogeneic Mesenchymal Stem Cell Therapy in AllotransplantationStem Cell Reviews and Reports, 2014
- Mesenchymal Stromal Cells: Sensors and Switchers of InflammationCell Stem Cell, 2013
- Concise review: Mesenchymal stem cell treatment for ischemic kidney diseaseStem Cells, 2013